Department of Hepatobiliary Surgery, Hainan Provincial Peoples Hospital, Haikou 570311, Peoples Republic of China.
Cell Biol Int. 2011 Aug;35(8):799-802. doi: 10.1042/CBI20110099.
Cholangiocarcinoma is the second most common primary hepatic tumour originating from biliary tract epithelial cells with poor prognosis. Enhanced c-Myc protein expression contributes to many aspects of tumour cell biology. Although the ability of c-Myc to drive unrestricted cell proliferation and to inhibit cell differentiation had been well recognized, whether down-regulated c-Myc expression can inhibit tumour cell invasion still remains to be explored. The c-Myc ASODN (antisense oligodeoxyribonucleotide) and NSODN (nonsense oligodeoxyribonucleotide) were designed, synthesized and transfected into human QBC939 bile duct carcinoma cells using the Lipofectamine 2000 reagent. The protein expression of c-Myc was detected by Western blot. A transwell experiment was applied to evaluate the invasive capacity of the QBC939 cells. c-Myc ASODN could significantly suppress the c-Myc protein expression (P<0.05) and the invasion (P<0.01) of QBC939 cells transfected with c-Myc ASODN compared with that in the control and c-Myc NSODN-transfected group. Thus in the present study we show that down-regulation of c-Myc expression can inhibit the invasion of QBC939 cells in vitro.
胆管癌是第二常见的原发性肝肿瘤，源自胆道上皮细胞，预后不良。增强的 c-Myc 蛋白表达有助于肿瘤细胞生物学的许多方面。虽然 c-Myc 驱动无限制的细胞增殖和抑制细胞分化的能力已经得到很好的认识，但下调 c-Myc 表达是否能抑制肿瘤细胞侵袭仍有待探索。设计、合成了 c-Myc ASODN（反义寡脱氧核苷酸）和 NSODN（无意义寡脱氧核苷酸），并使用 Lipofectamine 2000 试剂转染到人 QBC939 胆管癌细胞中。通过 Western blot 检测 c-Myc 的蛋白表达。通过 Transwell 实验评估 QBC939 细胞的侵袭能力。与对照组和转染 c-Myc NSODN 的组相比，c-Myc ASODN 可显著抑制转染 c-Myc ASODN 的 QBC939 细胞的 c-Myc 蛋白表达（P<0.05）和侵袭（P<0.01）。因此，在本研究中，我们表明下调 c-Myc 表达可以抑制 QBC939 细胞在体外的侵袭。
